Date and Time | Title | |
---|---|---|
Aug 21, 2020 9:54am - 10:00am (Eastern) | WELCOME AND INTRODUCTION Session Chair: Dr. Yehuda Yandeslman, MD and Mikhail N. Kosiborod, MD
| |
Aug 21, 2020 10:00am - 11:49am (Eastern) | Session 1: COVID-19 in DM & CVD Session Chair: Derek LeRoith, MD, PhD Obesity, a Major Predictor of Mortality by COVID-19: Associations with DM & CVD and Implications for Therapy Christos S. Mantzoros, MD, PhD
CVD Incidence & MOA in COVID-19: Vascular, Inflammatory & Thrombosis Implications Mansoor Husain, MD
Ongoing Research of COVID-19 Complications & Management - Focus on DARE-19 Mikhail N. Kosiborod, MD
Diabetes and the COVID-19 Pandemic Zachary Bloomgarden, MD
The Impact of COVID-19 on Cardiovascular Care & the Post-Pandemic Future of Cardiovascular Prevention Laurence Sperling, MD
Panel Discussion & Live Q&A | |
Aug 21, 2020 11:49am - 12:00pm (Eastern) | LIVE Q&A —Session 1: COVID-19 in DM & CVD Session Chair: Derek LeRoith, MD, PhD Obesity, a Major Predictor of Mortality by COVID-19: Associations with DM & CVD and Implications for Therapy Christos S. Mantzoros, MD, PhD
CVD Incidence & MOA in COVID-19: Vascular, Inflammatory & Thrombosis Implications Mansoor Husain, MD
Ongoing Research of COVID-19 Complications & Management - Focus on DARE-19 Mikhail N. Kosiborod, MD
Diabetes and the COVID-19 Pandemic Zachary Bloomgarden, MD
The Impact of COVID-19 on Cardiovascular Care & the Post-Pandemic Future of Cardiovascular Prevention Laurence Sperling, MD
Panel Discussion & Live Q&A | |
Aug 21, 2020 12:00pm - 12:59pm (Eastern) | Session 2: CONTEMPORARY CONCEPTS & MANAGEMENT OF DM & ASCVD Session Chair: Laurence Sperling, MD Epigenetic Modification to Reduce CVD in People with DM Kausik Ray, MD
The Surgical Management of CAD in DM Michael E. Farkouh, MD
Update on CVOT's Michael H. Davidson, MD
Panel Discussion & Live Q&A | |
Aug 21, 2020 12:59pm - 1:20pm (Eastern) | LIVE Q&A —Session 2: CONTEMPORARY CONCEPTS & MANAGEMENT OF DM & ASCVD Session Chair: Laurence Sperling, MD Epigenetic Modification to Reduce CVD in People with DM Kausik Ray, MD
The Surgical Management of CAD in DM Michael E. Farkouh, MD
Update on CVOT's Michael H. Davidson, MD
Panel Discussion & Live Q&A | |
Aug 21, 2020 1:20pm - 2:05pm (Eastern) | Industry Session (Non-CME): VASCEPA® (icosapent ethyl): Elevating the Standard of Care – Sponsored by: AMARIN | |
Aug 21, 2020 2:05pm - 3:24pm (Eastern) | Session 3: CONTROVERSIES IN LIPID MANAGEMENT Session Chairs: Paul S. Jellinger, MD, Kausik Ray, MD
"Back to the Future" with Lipid Therapy Norman E. Lepor, MD
Should High Triglycerides Be Managed in Addition to a Statin & EPA? Sergio Fazio, MD, PhD
DEBATE: SHOULD TREATMENT WITH PCSK9I BE RESERVED FOR LDL >100 Yes Jennifer G. Robinson, MD No Steven E. Nissen, MD Rebuttal Rebuttal Panel, Q&A, Audience Voting
| |
Aug 21, 2020 3:24pm - 3:45pm (Eastern) | LIVE Q&A — Session 3: CONTROVERSIES IN LIPID MANAGEMENT Session Chairs: Paul S. Jellinger, MD, Kausik Ray, MD
"Back to the Future" with Lipid Therapy Norman E. Lepor, MD
Should High Triglycerides Be Managed in Addition to a Statin & EPA? Sergio Fazio, MD, PhD
DEBATE: SHOULD TREATMENT WITH PCSK9I BE RESERVED FOR LDL >100 Yes Jennifer G. Robinson, MD No Steven E. Nissen, MD Rebuttal Rebuttal Panel, Q&A, Audience Voting
| |
Aug 21, 2020 3:45pm - 5:03pm (Eastern) | Session 4: HEART IN DIABETES WITH CIRCULATION Session Chair: Biykem Bozkurt, MD, PhD
Introduction Biykem Bozkurt, MD, PhD
GLP1ra Exenatide and Heart Failure Outcomes Robert J. Mentz, MD
The Diabetes Paradox in Aortic Aneurysm Joshua Beckman, MD
Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of CVD in T1DM Mrya A. Lipes, MD
Heart Failure Risk Stratification and Efficacy of SGLT2i in Patients with T2DM Benjamin M. Scirica, MD
Sugar and Artifically-Sweetened Beverages and CVD Risk- Reason for Concern? Alice H. Lichenstein, D. Sc
Panel, Live Q&A
| |
Aug 21, 2020 5:02pm - 5:25pm (Eastern) | LIVE Q&A — Session 4: HEART IN DIABETES WITH CIRCULATION Session Chair: Biykem Bozkurt, MD, PhD
Introduction Biykem Bozkurt, MD, PhD
GLP1ra Exenatide and Heart Failure Outcomes Robert J. Mentz, MD
The Diabetes Paradox in Aortic Aneurysm Joshua Beckman, MD
Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of CVD in T1DM Mrya A. Lipes, MD
Heart Failure Risk Stratification and Efficacy of SGLT2i in Patients with T2DM Benjamin M. Scirica, MD
Sugar and Artifically-Sweetened Beverages and CVD Risk- Reason for Concern? Alice H. Lichenstein, D. Sc
Panel, Live Q&A
| |
Aug 21, 2020 5:25pm - 6:29pm (Eastern) | Day 1 Summary, Live Q&A 5:25pm - 6:15pm | |
Aug 22, 2020 10:00am - 10:55am (Eastern) | Session 5: WOMEN & CVD Session Chair: Norman E. Lepor, MD
Cardiovascular Disease Risk Reduction in Menopausal Women Gina P. Lundberg, MD
Gender Differences in Cardiovascular Imaging Matthew J. Budoff, MD
Sex Differences in DM & CVD Across Outcome Studies Neha J. Pagidipati, MD
Panel Discussion & Live Q&A | |
Aug 22, 2020 10:55am - 11:20am (Eastern) | LIVE Q&A — Session 5: WOMEN & CVD Session Chair: Norman E. Lepor, MD
Cardiovascular Disease Risk Reduction in Menopausal Women Gina P. Lundberg, MD
Gender Differences in Cardiovascular Imaging Matthew J. Budoff, MD
Sex Differences in DM & CVD Across Outcome Studies Neha J. Pagidipati, MD
Panel Discussion & Live Q&A | |
Aug 22, 2020 11:20am - 12:36pm (Eastern) | Session 6: ADVANCES IN ANTI-THROMBOTICS IN DIABETES Session Chair: Deepak L. Bhatt, MD
Insights on Anti-Thrombotics Strategies in Diabetes from THEMIS PCI Philippe Gabriel Steg, MD
Anti-Thrombotics Therapy in Diabetes Richard C. Becker, MD
COMPASS Deepak L. Bhatt, MD
Panel Discussion & Live Q&A | |
Aug 22, 2020 12:37pm - 12:40pm (Eastern) | QUICK BREAK BEFORE "LUMINARY IN CARDIOMETABOLIC MEDICINE" AWARD PRESENTATION QUICK BREAK BEFORE "LUMINARY IN CARDIOMETABOLIC MEDICINE" AWARD PRESENTATION Grab your lunch and your favorite beverage for the upcoming award presentation and keynote. | |
Aug 22, 2020 12:40pm - 1:18pm (Eastern) | AWARD PRESENTATION "Luminary in Cardiometabolic Medicine" Presented by: Deepak L. Bhatt, MD, Mikhail N. Kosiborod, MD, Yehuda Handelsman, MD
Awards Presentation
KEYNOTE: SGLT2i and the Birth of 2 PARADIGM SHIFTS in Clinical Care Eugene Braunwald, MD
Live Q&A | |
Aug 22, 2020 1:18pm - 1:45pm (Eastern) | LIVE Q&A – AWARD PRESENTATION "Luminary in Cardiometabolic Medicine" Presented by: Deepak L. Bhatt, MD, Mikhail N. Kosiborod, MD, Yehuda Handelsman, MD
Awards Presentation
KEYNOTE: SGLT2i and the Birth of 2 PARADIGM SHIFTS in Clinical Care Eugene Braunwald, MD
Live Q&A | |
Aug 22, 2020 1:45pm - 2:15pm (Eastern) | The Continuum of Heart Failure – Sponsored by: Boehringer Ingelheim & Lilly – Industry Session (Non-CME) | |
Aug 22, 2020 2:15pm - 3:18pm (Eastern) | Session 7: PRACTICE RECOMMENDATIONS IN DIABETES & ASCVD - AN UPDATE Session Chairs: Lawrence A. Leiter, MD, Sergio Fazio, MD, PhD
Contemporary Lipid Management Recommendations in the Prevention of CVD Christie M. Ballantyne, MD
ESC/EASD 2019 CVD in DM Guidelines Peter J. Grant, MD
ADA-EASD Practice Recommendations' 2019 Update David A. D'Alessio, MD
AACE DM & Lipids Practice Recommendations Yehuda Handelsman, MD
Panel Discussion & Live Q&A | |
Aug 22, 2020 3:18pm - 3:35pm (Eastern) | LIVE Q&A — Session 7: PRACTICE RECOMMENDATIONS IN DIABETES & ASCVD - AN UPDATE Session Chairs: Lawrence A. Leiter, MD, Sergio Fazio, MD, PhD
Contemporary Lipid Management Recommendations in the Prevention of CVD Christie M. Ballantyne, MD
ESC/EASD 2019 CVD in DM Guidelines Peter J. Grant, MD
ADA-EASD Practice Recommendations' 2019 Update David A. D'Alessio, MD
AACE DM & Lipids Practice Recommendations Yehuda Handelsman, MD
Panel Discussion & Live Q&A | |
Aug 22, 2020 3:35pm - 4:56pm (Eastern) | CME Supported Symposium: The Prevention and Management of the Heart Failure This CME Symposium is supported by an educational grant from AstraZeneca. Symposium Chairs: Javed Butler, MD, Yehuda Handelsman, MD Agenda: Introduction Epidemiology and Pathophysiology of HF
Preventing HF & HF Adverse Outcomes: A Look at the Evidence
The Present and Future Management of HFrEF and HFpEF Panel Discussion: Moderator Live Q&A
| |
Aug 22, 2020 4:56pm - 5:15pm (Eastern) | LIVE Q&A — CME Supported Symposium: The Prevention and Management of the Heart Failure Symposium Chairs: Javed Butler, MD, Yehuda Handelsman, MD
Introduction
Epidemiology and Pathophysiology of HF Mikhail N. Kosiborod, MD
Preventing HF & HF Adverse Outcomes: A Look at the Evidence Javed Butler, MD
The Present and Future Management of HFrEF and HFpEF Biykem Bozkurt, MD, PhD
Panel Discussion: Practical Management of HF - Case Based Biykem Bozkurt, MD, PhD, Yehuda Handelsman, MD Mikhail N. Kosiborod, MD, Christian W. Mende, MD, Muthiah Vaduganathan, MD Moderator Javed Butler, MD Live Q&A
| |
Aug 22, 2020 5:15pm - 6:17pm (Eastern) | Day 2 Summary, Live Q&A 5:15pm - 6:15pm | |
Aug 23, 2020 10:00am - 11:27am (Eastern) | Session 8: MANAGEMENT OF HYPERGLYCEMIA TO IMPROVE OUTCOMES Session Chairs: George Grunberger, MD, Daniel Einhorn,MD
Preventing Diabetes to Prevent CVD: Is it Chicken or Egg? (or Turkey?!) Silvio E. Inzucchi, MD
Management Hyperglycemia in T2DM with Class 4-5 CKD Vivian A. Fonseca, MD
The Combination of SGLT2i and GLP1-ra's Impact on CVD Ralph A. DeFronzo, MD
Adjunctive Therapies for Type 1 Diabetes: Thinking Beyond Glucose Control Richard E. Pratley, MD
Panel Discussion & Live Q&A | |
Aug 23, 2020 11:27am - 11:40am (Eastern) | LIVE Q&A – Session 8: MANAGEMENT OF HYPERGLYCEMIA TO IMPROVE OUTCOMES Session Chairs: George Grunberger, MD, Daniel Einhorn,MD
Preventing Diabetes to Prevent CVD: Is it Chicken or Egg? (or Turkey?!) Silvio E. Inzucchi, MD
Management Hyperglycemia in T2DM with Class 4-5 CKD Vivian A. Fonseca, MD
The Combination of SGLT2i and GLP1-ra's Impact on CVD Ralph A. DeFronzo, MD
Adjunctive Therapies for Type 1 Diabetes: Thinking Beyond Glucose Control Richard E. Pratley, MD
Panel Discussion & Live Q&A | |
Aug 23, 2020 11:40am - 12:32pm (Eastern) | Session 9:THE TREATMENT OF DIABETES Session Chairs: Ralph A. DeFronzo,MD, Vivian A. Fonseca,MD DEBATE: EARLY COMBINATION VS SEQUENTIAL THERAPY- IMPACT ON DM & CVD
Sequential Therapy David M. Nathan,MD
Early Combination Therapy Stefano Del Prato, MD
Panel, Q&A, Audience Voting
| |
Aug 23, 2020 12:33pm - 12:45pm (Eastern) | LIVE VOTING + Q&A — Session 9: THE TREATMENT OF DIABETES Session Chairs: Ralph A. DeFronzo,MD, Vivian A. Fonseca,MD DEBATE: EARLY COMBINATION VS SEQUENTIAL THERAPY- IMPACT ON DM & CVD
Sequential Therapy David M. Nathan,MD
Early Combination Therapy Stefano Del Prato, MD
Panel, Q&A, Audience Voting
| |
Aug 23, 2020 12:45pm - 1:16pm (Eastern) | Industry Session (Non-CME): The Next Horizon in the Heart Failure Treatment Paradigm for Patients with HFrEF – Sponsored by: AstraZeneca | |
Aug 23, 2020 1:16pm - 1:30pm (Eastern) | LIVE Q&A – Industry Session (Non-CME): The Next Horizon in the Heart Failure Treatment Paradigm for Patients with HFrEF – Sponsored by: AstraZeneca | |
Aug 23, 2020 1:30pm - 2:45pm (Eastern) | Session 10: HEART IN DIABETES WITH JACC Session Chair: Michael E. Farkouh, MD
Introduction Michael E. Farkouh, MD
Atrial Fibrillation and Diabetes Mellitus Allen Wang, MD
Therapeutic Care, Health-Related Quality of Life, Clincial Outcomes in Comorbid HFrEF and DM: The CHAMP-HF Registry Muthiah Vaduganathan, MD
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes Daniel Gudbjartsson, PhD
SGLT2 Inhibition and Cardiorenal Protection Julie A. Lovshin, MD, PhD
Individualizing Revascularization Strategy for Diabetic Patients with Multivessel CAD David J. Cohen, MD
Panel, Live Q&A
| |
Aug 23, 2020 2:45pm - 3:10pm (Eastern) | LIVE Q&A Session 10: HEART IN DIABETES WITH JACC Session Chair: Michael E. Farkouh, MD
Introduction Michael E. Farkouh, MD
Atrial Fibrillation and Diabetes Mellitus Allen Wang, MD
Therapeutic Care, Health-Related Quality of Life, Clincial Outcomes in Comorbid HFrEF and DM: The CHAMP-HF Registry Muthiah Vaduganathan, MD
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes Daniel Gudbjartsson, PhD
SGLT2 Inhibition and Cardiorenal Protection Julie A. Lovshin, MD, PhD
Individualizing Revascularization Strategy for Diabetic Patients with Multivessel CAD David J. Cohen, MD
Panel, Live Q&A
| |
Aug 23, 2020 3:10pm - 4:37pm (Eastern) | Session 11: HEART FAILURE: STATE-OF-THE-ART Session Chairs: Mansoor Husain, MD
Impact of Blood Pressure:Variability on CHF Peter Reaven, MD
HF in DM - Is it Morbidity Not Morbidity We Need to Focus on? Mark Kearney, MD
Physiologic Monitoring of Heart Failure Robert J. Chilton, DO
DAPA-HF and Next Steps with SGLT2 Inhibitors in Heart Failure John McMurray, MD
Panel Discussion & Live Q&A
| |
Aug 23, 2020 4:37pm - 5:00pm (Eastern) | LIVE Q&A — Session 11: HEART FAILURE: STATE-OF-THE-ART Session Chairs: Mansoor Husain, MD
Impact of Blood Pressure:Variability on CHF Peter Reaven, MD
HF in DM - Is it Morbidity Not Morbidity We Need to Focus on? Mark Kearney, MD
Physiologic Monitoring of Heart Failure Robert J. Chilton, DO
DAPA-HF and Next Steps with SGLT2 Inhibitors in Heart Failure John McMurray, MD
Panel Discussion & Live Q&A
| |
Aug 23, 2020 5:00pm - 6:30pm (Eastern) | Day 3 Summary, Live Q&A 5:00pm - 6:00pm | |
Aug 24, 2020 10:00am - 11:02am (Eastern) | Session 12: GLP1-RA IN ASCVD & THE KIDNEY Session Chairs: Richard E. Pratley, MD, Matthew R. Weir, MD
Mechanistic Insights into Cardiovascular Effects of GLP-1ra Nikolaus Marx, MD
GLP1-ra Impact on the Kidney Mark E. Cooper, AO, PhD
Role of GLP1-ra in Trials in HF Patients Javed Butler, MD
Panel Discussion & Live Q&A | |
Aug 24, 2020 11:02am - 11:15am (Eastern) | LIVE Q&A — GLP1-RA IN ASCVD & THE KIDNEY Session Chairs: Richard E. Pratley, MD, Matthew R. Weir, MD
Mechanistic Insights into Cardiovascular Effects of GLP-1ra Nikolaus Marx, MD
GLP1-ra Impact on the Kidney Mark E. Cooper, AO, PhD
Role of GLP1-ra in Trials in HF Patients Javed Butler, MD
Panel Discussion & Live Q&A | |
Aug 24, 2020 11:15am - 12:49pm (Eastern) | Session 13: The Kidney & The Heart Session Chairs: Christian W. Mende,MD, Robert J. Chilton, DO 11:15am - 11:35am The Role of Sodium Restrictions in HF in Type 2 Diabetes Jeffrey Testanti, MD 11:35am - 11:55am Effects of SGLT2i on BP and CKD Progression: Is it Dependent or Independent of BP? Matthew R. Weir, MD 11:55am - 12:15pm How Do SGLT2i Reduce Cardiorenal Outcomes and Atrial Fibrillations Subodh Verman, MD 12:15pm - 12:35pm Impact of Kidney Function on Mortality in the CVOT's George L. Bakris, MD 12:35pm - 1:00pm Panel Discussion & Live Q&A | |
Aug 24, 2020 12:49pm - 1:00pm (Eastern) | LIVE Q&A — Session 12: The Kidney & The Heart Session Chairs: Christian W. Mende,MD, Robert J. Chilton, DO 11:15am - 11:35am The Role of Sodium Restrictions in HF in Type 2 Diabetes Jeffrey Testanti, MD 11:35am - 11:55am Effects of SGLT2i on BP and CKD Progression: Is it Dependent or Independent of BP? Matthew R. Weir, MD 11:55am - 12:15pm How Do SGLT2i Reduce Cardiorenal Outcomes and Atrial Fibrillations Subodh Verma, MD 12:15pm - 12:35pm Impact of Kidney Function on Mortality in the CVOT's George L. Bakris, MD 12:35pm - 1:00pm Panel Discussion & Live Q&A | |
Aug 24, 2020 1:00pm - 1:45pm (Eastern) | Industry Session (Non-CME): Atherosclerotic Cardiovascular Disease (ASCVD) in Diabetes: Identifying High Risk and Reducing the Burden of Elevated LDL-C – Sponsored by: Novartis | |
Aug 24, 2020 1:45pm - 2:49pm (Eastern) | Session 14: Technology & Digital Health Session Chair: Christos S. Mantzoros, MD, PhD 1:45pm - 2:05pm Artificial Intelligence in the Future Management of Cardiovascular Disease and Diabetes Irving K, Loh, MD 2:05pm - 2:25pm The Implications of Digital Health for Cardiometabolic Conditions Michael P. Snyder, PhD 2:25pm - 2:45pm Is There an App for That? Role of Devices on Diabetes and CVD Management George Grunberger, MD 2:45pm - 3:00pm Panel Discussion & Live Q&A | |
Aug 24, 2020 2:49pm - 3:00pm (Eastern) | LIVE Q&A —Session 14: Technology & Digital Health Session Chair: Christos S. Mantzoros, MD, PhD 1:45pm - 2:05pm Artificial Intelligence in the Future Management of Cardiovascular Disease and Diabetes Irving K, Loh, MD 2:05pm - 2:25pm The Implications of Digital Health for Cardiometabolic Conditions Michael P. Snyder, PhD 2:25pm - 2:45pm Is There an App for That? Role of Devices on Diabetes and CVD Management George Grunberger, MD 2:45pm - 3:00pm Panel Discussion & Live Q&A | |
Aug 24, 2020 3:00pm - 3:39pm (Eastern) | Session 15: The Liver & The Heart Session Chair: Derek LeRoith, MD 3:00pm - 3:20pm NAFLD & the Heart as a Part of the Spectrum of Cardiometabolic Risk Laurence Sperling, MD 3:20pm - 3:40pm Emerging Management Options for NAFLD/NASH - Impact on Cardiometabolic Outcomes Christos S. Mantzoros, MD 3:40pm - 3:55pm Panel Discussion & Live Q&A
| |
Aug 24, 2020 3:39pm - 3:55pm (Eastern) | LIVE Q&A - Session 15: The Liver & The Heart Session Chair: Derek LeRoith, MD 3:00pm - 3:20pm NAFLD & the Heart as a Part of the Spectrum of Cardiometabolic Risk Laurence Sperling, MD 3:20pm - 3:40pm Emerging Management Options for NAFLD/NASH - Impact on Cardiometabolic Outcomes Christos S. Mantzoros, MD 3:40pm - 3:55pm Panel Discussion & Live Q&A
| |
Aug 24, 2020 3:55pm - 4:58pm (Eastern) | ABSTRACT ORAL PRESENTATION 3:55pm - 4:55pm 2020 ABSTRACT COMMITTEE: George Grunberger, MD *chair Zachary T. Bloomgarden, MD Matthew J. Budoff, MD Vivian A. Fonseca, MD Norman E. Lepor, MD Derek LeRoith, MD, PhD Laurence Sperling, MD *Abstracts will be published in: American Heart Journal Editor in Chief: Daniel Mark, MD, MPH | |
Aug 24, 2020 4:58pm - 5:59pm (Eastern) | Day 4 Summary, Live Q&A 5:00pm - 6:00pm | |
Aug 24, 2020 6:00pm - 7:03pm (Eastern) | REPLAY of SESSION 12 – GLP1-RA IN ASCVD & THE KIDNEY Session Chairs: Richard E. Pratley, MD, Matthew R. Weir, MD
Mechanistic Insights into Cardiovascular Effects of GLP-1ra Nikolaus Marx, MD
GLP1-ra Impact on the Kidney Mark E. Cooper, AO, PhD
Role of GLP1-ra in Trials in HF Patients Javed Butler, MD
Panel Discussion & Live Q&A | |
Feb 23, 2021 1:00pm - 2:00pm (Eastern) | HID Test 0223 |